Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CervoMed (CRVO) EBITDA Margin (2023 - 2025)

CervoMed (CRVO) has disclosed EBITDA Margin for 8 consecutive years, with 92680.47% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 9236720.0% to 92680.47% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 674.32% through Dec 2025, down 50761.0% year-over-year, with the annual reading at 674.32% for FY2025, 50761.0% down from the prior year.
  • EBITDA Margin hit 92680.47% in Q4 2025 for CervoMed, down from 2393.3% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 140.87% in Q3 2023 to a low of 92680.47% in Q4 2025.
  • Historically, EBITDA Margin has averaged 8061.88% across 3 years, with a median of 247.37% in 2024.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 18127bps in 2024 and later plummeted -9236720bps in 2025.
  • Year by year, EBITDA Margin stood at 94.85% in 2023, then plummeted by -230bps to 313.27% in 2024, then tumbled by -29485bps to 92680.47% in 2025.
  • Business Quant data shows EBITDA Margin for CRVO at 92680.47% in Q4 2025, 2393.3% in Q3 2025, and 357.3% in Q2 2025.